{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:20:54Z","timestamp":1793852454464,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Constellation Pharmaceuticals, a Novartis Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41591-025-03572-3","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T06:04:16Z","timestamp":1741586656000},"page":"1531-1538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0355-6368","authenticated-orcid":false,"given":"Raajit K.","family":"Rampal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Grosicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Chraniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-5712","authenticated-orcid":false,"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-1309","authenticated-orcid":false,"given":"Aaron T.","family":"Gerds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-8607","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Lucchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-5400","authenticated-orcid":false,"given":"Stephen T.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Kuykendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Patriarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"\u00c1lvarez-Larr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-7972","authenticated-orcid":false,"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9525-143X","authenticated-orcid":false,"given":"Joseph M.","family":"Scandura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah-Katharina","family":"Kays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Boxhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Jegg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire N.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"3572_CR1","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.clml.2024.02.015","volume":"24","author":"A Yacoub","year":"2024","unstructured":"Yacoub, A., Twardowski, N., Britt, A. & Shraim, N. SOHO state of the art updates and next questions | early intervention in myelofibrosis: where are we and does it matter? Clin. Lymphoma Myeloma Leuk. 24, 506\u2013511 (2024).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"3572_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ajh.26857","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi, A. Primary myelofibrosis: 2023 update on diagnosis, risk\u2010stratification, and management. Am. J. Hematol. 98, 801\u2013821 (2023).","journal-title":"Am. J. Hematol."},{"key":"3572_CR3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391\u20132405 (2016).","journal-title":"Blood"},{"key":"3572_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ijlh.14086","volume":"45","author":"ZY Ng","year":"2023","unstructured":"Ng, Z. Y., Fuller, K. A., Mazza\u2010Parton, A. & Erber, W. N. Morphology of myeloproliferative neoplasms. Int. J. Lab. Hematol. 45, 59\u201370 (2023).","journal-title":"Int. J. Lab. Hematol."},{"key":"3572_CR5","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1097\/HS9.0000000000000424","volume":"4","author":"P Bose","year":"2020","unstructured":"Bose, P. & Verstovsek, S. JAK inhibition for the treatment of myelofibrosis: limitations and future perspectives. Hemasphere 4, e424 (2020).","journal-title":"Hemasphere"},{"key":"3572_CR6","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison, C. N. et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 30, 1701\u20131707 (2016).","journal-title":"Leukemia"},{"key":"3572_CR7","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","volume":"126","author":"M Deininger","year":"2015","unstructured":"Deininger, M. et al. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood 126, 1551\u20131554 (2015).","journal-title":"Blood"},{"key":"3572_CR8","first-page":"456","volume":"20","author":"H Levavi","year":"2022","unstructured":"Levavi, H., Hoffman, R. & Marcellino, B. K. JAK inhibitors in the treatment of myelofibrosis. Clin. Adv. Hematol. Oncol. 20, 456\u2013467 (2022).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"3572_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.12703\/r\/12-23","volume":"12","author":"W Vainchenker","year":"2023","unstructured":"Vainchenker, W. et al. Recent advances in therapies for primary myelofibrosis. Fac. Rev. 12, 23 (2023).","journal-title":"Fac. Rev."},{"key":"3572_CR10","doi-asserted-by":"publisher","first-page":"670580","DOI":"10.1155\/2015\/670580","volume":"2015","author":"J Mondet","year":"2015","unstructured":"Mondet, J., Hussein, K. & Mossuz, P. Circulating cytokine levels as markers of inflammation in Philadelphia negative myeloproliferative neoplasms: diagnostic and prognostic interest. Mediators Inflamm. 2015, 670580 (2015).","journal-title":"Mediators Inflamm."},{"key":"3572_CR11","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi, A. et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J. Clin. Oncol. 29, 1356\u20131363 (2011).","journal-title":"J. Clin. Oncol."},{"key":"3572_CR12","first-page":"2508","volume":"141","author":"A Dunbar","year":"2023","unstructured":"Dunbar, A. et al. CXCL8\/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis. Blood 141, 2508\u20132519 (2023).","journal-title":"Blood"},{"key":"3572_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","volume":"33","author":"M Kleppe","year":"2018","unstructured":"Kleppe, M. et al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell 33, 29\u201343.e7 (2018).","journal-title":"Cancer Cell"},{"key":"3572_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.molcel.2014.08.024","volume":"56","author":"JD Brown","year":"2014","unstructured":"Brown, J. D. et al. NF-\u03baB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol. Cell 56, 219\u2013231 (2014).","journal-title":"Mol. Cell"},{"key":"3572_CR15","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1038\/s41375-021-01405-z","volume":"35","author":"J Mascarenhas","year":"2021","unstructured":"Mascarenhas, J., Gerds, A. & Verstovsek, S. Paradigm shift: combination BET and JAK inhibition in myelofibrosis. Leukemia 35, 3361\u20133363 (2021).","journal-title":"Leukemia"},{"key":"3572_CR16","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1021\/acs.jmedchem.5b01882","volume":"59","author":"BK Albrecht","year":"2016","unstructured":"Albrecht, B. K. et al. Identification of a benzoisoxazoloazepine inhibitor (CPI-0610) of the bromodomain and extra-terminal (BET) family as a candidate for human clinical trials. J. Med. Chem. 59, 1330\u20131339 (2016).","journal-title":"J. Med. Chem."},{"key":"3572_CR17","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1200\/JCO.22.01972","volume":"41","author":"J Mascarenhas","year":"2023","unstructured":"Mascarenhas, J. et al. MANIFEST: pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naive myelofibrosis. J. Clin. Oncol. 41, 4993\u20135004 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3572_CR18","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.1182\/bloodadvances.2023010628","volume":"7","author":"V Gupta","year":"2023","unstructured":"Gupta, V. et al. Matching-adjusted indirect comparison of pelabresib\/ruxolitinib combination vs JAKi monotherapy in myelofibrosis. Blood Adv. 7, 5421\u20135432 (2023).","journal-title":"Blood Adv."},{"key":"3572_CR19","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.2217\/fon-2022-0484","volume":"18","author":"CN Harrison","year":"2022","unstructured":"Harrison, C. N. et al. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. Future Oncol. 18, 2987\u20132997 (2022).","journal-title":"Future Oncol."},{"key":"3572_CR20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek, S. et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366, 799\u2013807 (2012).","journal-title":"N. Engl. J. Med."},{"key":"3572_CR21","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison, C. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787\u2013798 (2012).","journal-title":"N. Engl. J. Med."},{"key":"3572_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani, A. et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 1, 643\u2013651 (2015).","journal-title":"JAMA Oncol."},{"key":"3572_CR23","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa, R. A. et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor\u2013na\u00efve patients with myelofibrosis. J. Clin. Oncol. 35, 3844\u20133850 (2017).","journal-title":"J. Clin. Oncol."},{"key":"3572_CR24","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","volume":"4","author":"J Mascarenhas","year":"2018","unstructured":"Mascarenhas, J. et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis. JAMA Oncol. 4, 652 (2018).","journal-title":"JAMA Oncol."},{"key":"3572_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103862","volume":"180","author":"F Passamonti","year":"2022","unstructured":"Passamonti, F. et al. Anemia in myelofibrosis: current and emerging treatment options. Crit. Rev. Oncol. Hematol. 180, 103862 (2022).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"3572_CR26","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1182\/blood-2022-162657","volume":"140","author":"AT Gerds","year":"2022","unstructured":"Gerds, A. T., Harrison, C., Thompson, S., Snopek, F. & Pemmaraju, N. The burden of illness and the incremental burden of transfusion dependence in myelofibrosis in the United States. Blood 140, 3974\u20133975 (2022).","journal-title":"Blood"},{"key":"3572_CR27","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.clml.2017.05.015","volume":"17","author":"CB Miller","year":"2017","unstructured":"Miller, C. B. et al. Practical measures of clinical benefit with ruxolitinib therapy: an exploratory analysis of COMFORT-I. Clin. Lymphoma Myeloma Leuk. 17, 479\u2013487 (2017).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"3572_CR28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-023-01471-z","volume":"16","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek, S., Mesa, R. A., Livingston, R. A., Hu, W. & Mascarenhas, J. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety. J. Hematol. Oncol. 16, 82 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"3572_CR29","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1182\/bloodadvances.2022009311","volume":"7","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek, S. et al. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. Blood Adv. 7, 3582\u20133591 (2023).","journal-title":"Blood Adv."},{"key":"3572_CR30","doi-asserted-by":"publisher","unstructured":"Daskalopoulou, C. et al. Myelofibrosis symptom assessment form total symptom score version 4.0: measurement properties from the MOMENTUM phase 3 study. Qual. Life Res. https:\/\/doi.org\/10.1007\/s11136-024-03855-1 (2024).","DOI":"10.1007\/s11136-024-03855-1"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03572-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03572-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03572-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:01:25Z","timestamp":1747738885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03572-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3572"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03572-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report the following competing interests. R.K.R. has received grants from MorphoSys\/Constellation, Ryvu, Stemline and Zentalis, consultation fees from GlaxoSmithKline, Incyte, AbbVie, BMS-Celgene, Novartis, Zentalis, Promedior, CTI, Blueprint, Stemline, Galectco, PharmEssentia, Disc Medicines, Sunimoto Dainippon, Servier, Karyopharm and Cogent Bio, honoraria fees from Karyopharm, Sunimoto Dainippon and Protagonist, participated on a Data Safety Monitoring Board or Advisory Board for Disc Medicines and Merck, and received advisory fees from the MPN Research Foundation. D.C. has received consultation fees from Janssen, honoraria fees from Astellas, Amgen, BMS, Janssen, AstraZeneca and AbbVie, and support for attending meetings and\/or travel from Gilead Sciences, Ryvu Therapeutics and AbbVie. E.A. has received consulting\/advisory board fees from Ascentage, BMS, GlaxoSmithKline, Incyte, MorphoSys\/Novartis, Pfizer and Takeda. P.B. has received research support from MorphoSys to his institution for the conduct of this clinical trial, institutional grants from Incyte, BMS, CTI BioPharma (a Sobi company), MorphoSys, Kartos, Telios, Karyopharm, Sumitomo, Janssen, Geron, Ionis, Disc, Blueprint and Cogent; consultation fees from Incyte, BMS, CTI BioPharma (a Sobi company), GlaxoSmithKline, AbbVie, MorphoSys, Karyopharm, Sumitomo, PharmaEssentia, Morphic, Jubilant, Ionis, Disc, Blueprint, Cogent, Ono and Novartis; honoraria fees from Incyte, Sumitomo, GlaxoSmithKline, PharmaEssentia, AbbVie, CTI BioPharma (a Sobi company) and Novartis; holds a study steering committee membership with Blueprint, Geron and Karyopharm, a steering committee membership with Sumitomo, Keros, GlaxoSmithKline and Karyopharm and a leadership role in a scientific advisory board with PharmaEssentia; is an advisory board member for Raythera; and had received MD Anderson Cancer Center Support grant P30 CA016672 from the National Institutes of Health (National Cancer Institute). A.T.G. has received consulting fees from Novartis (MorphoSys), PharmaEssentia, GlaxoSmithKline (Sierra Oncology), Sobi (CTI Biopharma), AbbVie, Merck (Imago Biosciences), Kartos, Telios, BMS, Rain Oncology, Disc Medicine and Agios. A.M.V. has received honoraria fees from Incyte, Novartis, AbbVie, GlaxoSmithKline, BMS, MorphoSys and AOP, participated on a Data Safety Monitoring Board or Advisory Board from Incyte, Novartis, AOP, MorphoSys and Roche. F.P. has received consultation and honoraria fees from Novartis, Celgene, AOP, Sierra Oncology and CTI. S.-E.L. declares no personal or financial conflicts of interests related to this manuscript, has received consulting\/advisory board fees from BMS, GSK, Novartis and PharmaEssentia, and received an institutional grant from PharmaEssentia. V.G. has received grants from AbbVie and Novartis, consultation fees from GlaxoSmithKline, Incyte, AbbVie, BMS-Celgene and Novartis, honoraria fees from GlaxoSmithKline, Novartis and AbbVie, support for attending meetings and\/or travel from GlaxoSmithKline and participated on a Data Safety Monitoring Board or Advisory Board from BMS-Celgene, Incyte, Daichii-Sankyo, AbbVie, Novartis and GlaxoSmithKline. A.L. has received consulting fees from AOP and Sanofi, honoraria fees from Grifols, Incyte, Novartis, Amgen, Pfizer, BMS, Sanofi and SOBI, support for attending meetings and\/or travel from Sanofi and BeiGene, and participated on a Data Safety Monitoring Board or Advisory Board for MorphoSys, Amgen, Protagonist, Grifols, SOBI, Novartis and Sanofi. S.T.O. has received consulting fees from Novartis, Kartos Therapeutics, Disc Medicine, Blueprint Medicines, AbbVie, Constellation\/MorphoSys, CTI BioPharma, Bristol Myers Squibb, Geron, GlaxoSmithKline\/Sierra Oncology, Cogent and Incyte. A.T.K. has received institutional grants from MorphoSys, Novartis, BMS, GlaxoSmithKline, Protagonist, Geron and Janssen, consultation fees from AbbVie, MorphoSys and Karyopharm, honoraria fees from PharmaEssentia, Incyte, BMS and CTI Biopharma, support for attending meetings and\/or travel support from PharmaEssentia, and participated on a Data Safety Monitoring Board or Advisory Board with Incyte. A.P. has received consulting fees from Sanofi and Sobi, honoraria fees from Sobi, Sanofi, Pfizer, Incyte, Alexion, Takeda, Novartis and BMS, and support for attending meetings and\/or travel from Alexion, Sobi and Sanofi. A.A.-L. received honoraria fees from AOP Health for participating in an advisory board and from Novartis and GSK for lectures. R.M. has received grants for research support from MorphoSys, CTI, BMS, Genentech, AbbVie, Incyte and GlaxoSmithKline, and consultation fees from MorphoSys, Incyte, BMS, Novartis, CTI and GlaxoSmithKline. J.-J.K. has received consultation fees from Novartis, AbbVie and GlaxoSmithKline, honoraria fees from Novartis, AOP Health and BMS, support for attending meetings and\/or travel from Novartis, and participated on a Data Safety Monitoring Board or Advisory Board from Incyte. M.T. has received advisory board fees from Novartis and Sumitomo, and research funding from BMS. J.M.S. received institutional research support from Constellation\/MorphoSys, advisory board fees from Constellation\/MorphoSys, grants from AbbVie (for research support, research support to institution, advisory board), SDP Oncology (for research support, research support to institution, advisory board), Karyopharm (for research support to institution, advisory board), Morphic (for research support), PharmaEssentia (for research support to institution, advisory board) and Protagonist (for research support to institution, advisory board), and consultation fees from SDP Oncology, Morphic, PharmaEssentia and Calico. D.L. has received consultation fees from AbbVie, Takeda and Novartis, honoraria fees from AbbVie, Roche, Novartis and Takeda, support for attending meetings and\/or travel from AbbVie and Roche, and participated on a Data Safety Monitoring Board or Advisory Board from AbbVie. M.H. is an employee of Constellation Pharmaceuticals, a Novartis Company. S.-K.K. is an employee of MorphoSys GmbH, Planegg, Germany, a Novartis Company. A.-M.J. is an employee of MorphoSys GmbH, Planegg, Germany, a Novartis Company. Q.L. is an employee of MorphoSys US Inc., Boston, MA, USA, a Novartis Company. R.B. is an employee of MorphoSys GmbH, Planegg, Germany, a Novartis Company. B.B. was an employee of Constellation Pharmaceuticals, Boston, MA, USA, a Novartis Company, and holds stock with Pfizer, Moderna, Eli Lily, Exelixis and Verastem. C.N.H. has received institutional grants from Constellation and Novartis, consultation fees from Novartis, MSD, Karyopharm, AOP, GlaxoSmithKline, BMS, Sobi, Galecto and CTI, honoraria fees from Novartis, MSD, Karyopharm, Sobi, GlaxoSmithKline and BMS, support for attending meetings and\/or travel from Novartis, participated on a Data Safety Monitoring Board or Advisory Board for BMS and Galecto, leadership role with Blood Cancer UK (Trustee; unpaid), EHA (Deputy Editor-in-Chief remunerated) and MPN Voice (Medical Director; unpaid), and holds stock or stock options with Chakana Medical Limited. J.M. has received grants from Incyte, Novartis, Geron, BMS, AbbVie, CTI\/SOBI, Karyopharm, Disc Medicines, Ajax, PharmaEssentia and Kartos, consultation fees from Incyte, CTI\/SOBI, BMS, MorphoSys, GlaxoSmithKline, AbbVie, Novartis, Roche, Merck, Pfizer, Geron, Karyopharm, PharmaEssentia, Disc Medicines, Blueprint Medicines, Keros, Galecto and Sumitomo, support for attending meetings and\/or travel from Kartos, and participated on a Data Safety Monitoring or Advisory Board with Galecto and Incyte. The remaining author(s) declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}